Literature DB >> 17617877

Treatment outcomes of 70 cases of early esophageal carcinoma: 12 years of experience.

J-H Kim1, H S Chung, Y H Youn, S W Park, S Y Song, J B Chung, C B Kim, Y C Lee.   

Abstract

Early esophageal cancer (EEC) has an excellent prognosis compared to advanced esophageal cancer. Nowadays, endoscopic mucosal resection (EMR) may offer another alternative to cure early cancers of the gastrointestinal tract. We aimed to evaluate the clinical outcomes of EEC in Korea after curative treatments; EMR or surgery. We retrospectively reviewed the medical records of patients diagnosed as EEC from January 1994 to August 2005 at Yonsei University Medical Center, Seoul, Korea. Among 888 patients diagnosed with esophageal cancer, 70 (7.9%) were included as EEC. Among them, 10 patients (14.3%) were treated by EMR, and 50 (71.4%) by operation. The treatment outcomes of EEC in relation to various clinicopathologic factors along with survival rates were analyzed. There were 18 cases (30%) of mucosal lesions and 42 cases (70%) of submucosal lesions. Overall 5-year survival rate was 84.3%. When comparing treatment outcomes between EMR-treated and operated groups, there were no significant differences in complete remission (80%vs. 84%), recurrence (20%vs. 16%) and 5-year survival rate (100%vs. 78.3%). EEC is a potentially curable entity with a good clinical prognosis. EMR can be considered as another treatment arm for EEC, along with surgical resection.

Entities:  

Mesh:

Year:  2007        PMID: 17617877     DOI: 10.1111/j.1442-2050.2007.00674.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  5 in total

1.  Endoscopic treatments for early esophageal cancer.

Authors:  Charles J Lightdale
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-12

2.  Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials.

Authors:  Aminah Jatoi; Nathan R Foster; James R Egner; Patrick A Burch; Philip J Stella; Joseph Rubin; Shaker R Dakhil; Daniel J Sargent; Brian R Murphy; Steven R Alberts
Journal:  Int J Oncol       Date:  2010-03       Impact factor: 5.650

3.  Surgical treatments for squamous cell carcinoma of the esophagus reaching to the muscularis mucosa or the upper third of the submucosal layer.

Authors:  Junya Oguma; Soji Ozawa; Yoshiro Saikawa; Yuko Kitagawa
Journal:  Oncol Lett       Date:  2010-05-01       Impact factor: 2.967

4.  Analysis of Survival Rates of Patients Diagnosed With Incipient Esophagic Cancer.

Authors:  Edmundo Carvalho Mauad; Maria do Rosario Dias de Oliveira Latorre; Thiago Buosi Silva; Ricardo Mauad Daher; Vinicius de Lima Vazquez; Antonio Talvane Torres Oliveira; Adhemar Longatto Filho
Journal:  World J Oncol       Date:  2010-02-01

5.  ADH1B and ALDH2 are associated with metachronous SCC after endoscopic submucosal dissection of esophageal squamous cell carcinoma.

Authors:  Kenichi Kagemoto; Yuji Urabe; Tomohiro Miwata; Shiro Oka; Hidenori Ochi; Yasuhiko Kitadai; Shinji Tanaka; Kazuaki Chayama
Journal:  Cancer Med       Date:  2016-03-31       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.